EECP (Enhanced External Counter Pulsation) benefits sustained at two years:
This article was originally published in Clinica
Vasomedical says that data is now available to show that the reduction in angina achieved using its Enhanced External Counter Pulsation (EECP) therapy is sustained at two years. The results come from an analysis of 254 patients from an International EECP patient registry at the University of Pittsburgh Graduate School of Public Health in Pennsylvania. Before EECP therapy, 80% of patients had severe angina. This figure fell to 16% immediately following treatment and remained at this level for the next two years, says the Westbury, New York firm.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.